Adnan Haider, MD
Endocrinology, Diabetes & Metabolism · Morgantown, WVNPI 1689871899
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,246 of the $2,571 with a category attached, or 87.4%. It is spread thinly across 27 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,076, 9.8 times the $110 reported in 2019.
Across 123 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$489
- Chiesi USA, Inc.$325
- Medtronic$322
- Xeris Pharmaceuticals, Inc.$191
- Insulet Corporation$189
- Lilly USA, LLC$167
- plus $888 from 21 others
Across 31 payments — averaging $322.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$10K
What the payments were for
- Speaking & faculty fees$32513%
- Food & beverage$2,24687%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $489 |
| Chiesi USA, Inc. | 1 | $325 |
| Medtronic(2 entities) | 14 | $322 |
| Xeris Pharmaceuticals, Inc. | 9 | $191 |
| Insulet Corporation | 9 | $189 |
| Lilly USA, LLC | 11 | $167 |
| Abbott | 7 | $143 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $81 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Boehringer Ingelheim | 3 | $77 |
| Cequr Corporation | 2 | $72 |
| Eisai Inc. | 2 | $59 |
| Amgen | 4 | $56 |
| Bayer | 3 | $52 |
| Sequel Med Tech, LLC | 2 | $44 |
| Dexcom, Inc. | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| BETA Bionics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$325
How this compares
$2,571 in reported general payments places this provider in the 65th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 410 | $575,595 |
| TrulicityDulaglutide | 222 | $332,123 |
| MounjaroTirzepatide | 243 | $325,992 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 80 | $211,605 |
| JardianceEmpagliflozin | 140 | $188,180 |
| FarxigaDapagliflozin Propanediol | 132 | $125,828 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $115,055 |
| ForteoTeriparatide | 23 | $108,633 |
| Levothyroxine Sodium | 441 | $103,151 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $74,523 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $51,312 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $47,475 |
| JanuviaSitagliptin Phosphate | 34 | $38,311 |
| Novolog FlexpenInsulin Aspart | 104 | $36,627 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $24,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Insulin Lispro | $167 | $778,472521 claims |
| Novo NordiskOzempic, Novolog | $489 | $584,052446 claims |
| Boehringer IngelheimJardiance | $77 | $188,180140 claims |
| AstraZenecaFarxiga | $16 | $125,828132 claims |
| Sanofi-aventis U.S. LLCLantus | $81 | $4,44911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Morgantown
- Jessica PeriniMorgantown$10K
- Jennifer TurnerMorgantown$6K
- Jennifer GiordanoMorgantown$2K
- Nadia BarghouthiMorgantown$1K
- Apoorva IyerMorgantown$1K
- Jeffrey Zen-Ji RicoMorgantown$1K
- Tariq LatifMorgantown$844
- Mehjabeen SadiqMorgantown$684
- Sarah FatimaMorgantown$292
- Ann-Marie BusickMorgantown$227
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.